MolDX: Melanoma Risk Stratification Molecular Testing

Molecular diagnostic tests for melanoma risk stratification are covered when the patient has a personal history of melanoma, is undergoing workup or treatment evaluation, is non-metastatic, has Stage T1b+ (or T1a with documented microstaging concern), and has a presumed SLNB risk >5% with disease characteristics within the test's intended use. The specific test must have Technical Assessment–supported clinical validity, clinical utility beyond existing factors, appropriate analytical validity, and equivalent or superior performance to other covered tests.

"Patient has a personal history of melanoma."

Sign up to see full coverage criteria, indications, and limitations.